With the recent development of highly specific CDK4/6 inhibitors (Palbociclib, Ribociclib, and Abemaciclib) and the approval of their use by the FDA for advanced metastatic breast cancer, designing multiple clinical trials using these agents for lung cancer have attracted great interest (9). This evidence concerns the gene CDK4 and lung cancer.